Healthcare Industry News: Anodyne
News Release - January 4, 2016
PLx Pharma Appoints Natasha Giordano as CEOExperienced Pharmaceutical Executive Brings 25 Years of Leadership and Marketing Expertise
HOUSTON--(Healthcare Sales & Marketing Network)--PLx Pharma Inc. (PLx), a privately-held, late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide safer and more effective aspirin products, announces that Natasha Giordano has been appointed as President and Chief Executive Officer, and as a member of the Company’s Board of Directors, effective January 1, 2016. Ms. Giordano will be replacing Ronald R. Zimmerman, who will remain on the Board of Directors and continue in a role as Founder and Senior Advisor providing support for pre-commercialization activities, regulatory affairs, and business development.
Ms. Giordano joins PLx Pharma with over 25 years’ experience as an accomplished and versatile senior leader successfully achieving enterprise-wide strategic and financial goals across industries with a focus on Pharmaceuticals and Healthcare Technologies. Ms. Giordano is proficient in building commercialization plans including developing sales forces, raising capital, and is a skilled turnaround specialist known for her novel risk mitigation approaches.
"We are excited to welcome Natasha to the PLx team as she is a strong leader with a broad range of sales, marketing, and management experience, which will be a invaluable asset for PLx Pharma’s success and future growth prospects,” noted Michael Valentino, Executive Chairman of the Board of PLx. “Within our industry, Natasha is highly valued for her decisive leadership skills, for building multi-functional and international teams and for her proven track record of revenue and profit growth. We are confident Natasha will be a driving force for PLx as we transition from the development phase to the commercial launch of our lead product, PL2200 Aspirin, a U.S. Food and Drug Administration approved aspirin product that has clinically demonstrated more reliable and predictable antiplatelet efficacy compared with enteric coated aspirin.”
"I am excited to be joining PLx Pharma at this critical pre-launch inflection point,” stated Ms. Giordano. “PL2200 Aspirin fills a substantial medical need to provide high-risk cardiovascular and neurology patients with more reliable and predictable antiplatelet efficacy while reducing the adverse gastric events common in an acute setting with enteric coated aspirin. I look forward to building on the compelling clinical data and initial market access work the PLx management team has begun and to successfully launching PL2200 Aspirin into the U.S. market in 2017.”
Prior to joining PLx Pharma, Ms. Giordano was President and CEO of Clear Point Learning, where she was responsible for positioning the Company for growth and for developing market messaging and sales strategies centered on partnering with Pharmaceutical companies to launch new products. Previous to that, Ms. Giordano was President and CEO of Healthcare Corporation of America, where she positioned the Company for a successful sale of its Pharmaceutical Benefits Management subsidiary, increased profitable revenue, raised capital, launched a Healthcare Technology Division. From 2010 to 2012, Ms. Giordano was the President and CEO of XAnodyne Pharmaceuticals, a privately held specialty pharmaceutical company, where she built a 150- person sales force and successfully launched Zipsor into the pain market. Earlier in her career, Ms. Giordano served in numerous roles at Cegedim, a global sales and marketing effectiveness solution provider, including President of Americas, following the firm’s acquisition of Dendrite. Before that, Ms. Giordano was the Director, Strategic Alliances & Sales Integration for Parke-Davis/Pfizer. There, she effectively deployed annual marketing plans for three multi-billion dollar strategic alliance partners, and led a primary care sales team, which grew to be ranked #1 nationally. Ms. Giordano also serves on the Board of Aceto Corporation (ACET).
Ms. Giordano received a B.S. in Nursing from Wagner College in New York.
About PLx Pharma
PLx Pharma Inc. is a late-stage specialty pharmaceutical company initially focused on developing our clinically validated and patent-protected PLxGuard™ delivery system to provide safer and more effective aspirin products. Our PLxGuard™ delivery system works by releasing active pharmaceutical ingredients into the duodenum, the first part of the small intestine immediately below the stomach, rather than in the stomach itself. We believe this improves the absorption of many drugs currently on the market or in development, and reduces acute gastrointestinal (GI) side effects—including erosions, ulcers and bleeding—associated with aspirin and ibuprofen, and potentially other drugs. To learn more about the Company and its pipeline, please visit www.plxpharma.com.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, timing and results of clinical trials and EMA and U.S. FDA authorizations. Forward-looking statements are based on PLx Pharma’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements. The forward-looking statements made herein speak only as of the date of this announcement and PLx Pharma undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Source: PLx Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.